IL140858A0 - Endogenous constitutively activated g protein-coupled orphan receptors - Google Patents

Endogenous constitutively activated g protein-coupled orphan receptors

Info

Publication number
IL140858A0
IL140858A0 IL14085899A IL14085899A IL140858A0 IL 140858 A0 IL140858 A0 IL 140858A0 IL 14085899 A IL14085899 A IL 14085899A IL 14085899 A IL14085899 A IL 14085899A IL 140858 A0 IL140858 A0 IL 140858A0
Authority
IL
Israel
Prior art keywords
protein
constitutively activated
orphan receptors
endogenous constitutively
coupled orphan
Prior art date
Application number
IL14085899A
Other languages
English (en)
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Priority to IL16044699A priority Critical patent/IL160446A0/xx
Publication of IL140858A0 publication Critical patent/IL140858A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/42—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL14085899A 1998-07-31 1999-07-30 Endogenous constitutively activated g protein-coupled orphan receptors IL140858A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL16044699A IL160446A0 (en) 1998-07-31 1999-07-30 Endogenous constitutively activated g protein-coupled orphan receptors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9487998P 1998-07-31 1998-07-31
US10630098P 1998-10-30 1998-10-30
US11090698P 1998-12-04 1998-12-04
US12185199P 1999-02-26 1999-02-26
PCT/US1999/017425 WO2000006597A2 (en) 1998-07-31 1999-07-30 Endogenous constitutively activated g protein-coupled orphan receptors

Publications (1)

Publication Number Publication Date
IL140858A0 true IL140858A0 (en) 2002-02-10

Family

ID=27492754

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14085899A IL140858A0 (en) 1998-07-31 1999-07-30 Endogenous constitutively activated g protein-coupled orphan receptors

Country Status (13)

Country Link
EP (1) EP1095275B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002521681A (cg-RX-API-DMAC7.html)
CN (1) CN1231762C (cg-RX-API-DMAC7.html)
AT (1) ATE432472T1 (cg-RX-API-DMAC7.html)
AU (1) AU751080B2 (cg-RX-API-DMAC7.html)
CA (1) CA2338543C (cg-RX-API-DMAC7.html)
DE (1) DE69940923D1 (cg-RX-API-DMAC7.html)
DK (1) DK1095275T3 (cg-RX-API-DMAC7.html)
IL (1) IL140858A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01001176A (cg-RX-API-DMAC7.html)
NO (1) NO20010509L (cg-RX-API-DMAC7.html)
NZ (1) NZ509429A (cg-RX-API-DMAC7.html)
WO (1) WO2000006597A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
CA2402392A1 (en) 2000-04-07 2001-10-18 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated known g protein-coupled receptors
AU2003218234A1 (en) * 2002-03-15 2003-09-29 Arena Pharmaceuticals, Inc. Methods of expressing non-endogenous g protein coupled receptors in cells
AU2003219030A1 (en) * 2002-03-22 2003-10-08 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with human g protein-coupled orphan receptor 21 (gpr21)
AU2003266238A1 (en) * 2002-08-05 2004-02-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1)
AU2003291967A1 (en) * 2002-12-20 2004-07-14 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
WO2005095990A1 (en) * 2004-03-25 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 52 (gpr52)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2220715C (en) * 1995-06-07 2004-11-02 Praecis Pharmaceuticals Incorporated Functional bioassay for g-protein coupled receptor agonists and antagonists
EP0862614A1 (en) * 1995-09-20 1998-09-09 Molecular Geriatrics Corporation Yeast receptor and g-protein fusion protein
EP0965041B1 (en) * 1997-04-14 2009-02-18 Arena Pharmaceuticals, Inc. A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease

Also Published As

Publication number Publication date
WO2000006597A2 (en) 2000-02-10
CN1323396A (zh) 2001-11-21
NO20010509D0 (no) 2001-01-30
CN1231762C (zh) 2005-12-14
AU5545999A (en) 2000-02-21
WO2000006597A9 (en) 2000-07-13
CA2338543C (en) 2009-12-29
ATE432472T1 (de) 2009-06-15
CA2338543A1 (en) 2000-02-10
DE69940923D1 (de) 2009-07-09
AU751080B2 (en) 2002-08-08
NZ509429A (en) 2002-06-28
MXPA01001176A (es) 2005-07-25
WO2000006597A3 (en) 2000-05-18
EP1095275B1 (en) 2009-05-27
JP2002521681A (ja) 2002-07-16
DK1095275T3 (da) 2009-09-28
NO20010509L (no) 2001-03-19
EP1095275A2 (en) 2001-05-02

Similar Documents

Publication Publication Date Title
MY127234A (en) Methods for assessing, improving, or maintaining urogenital health in postmenopausal women
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
WO2003047420A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
ATE215369T1 (de) Carbazolanaloge als selektive beta3-adrenergische agonisten
AUPO755097A0 (en) Receptor agonist and antagonist
ATE247470T1 (de) Neue substituierte imidazolverbindungen
JP2002526106A5 (cg-RX-API-DMAC7.html)
IT1313625B1 (it) Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
ATE227716T1 (de) 2-substituierte-1-piperidyl- benzimidazolverbindungen als orl1 rezeptor agonisten
DE69901714D1 (de) Elektrochemischer affinitätsassay
AR020442A1 (es) Agonistas de 5ht2serotonergicos para el tratamiento de glaucoma
BRPI0415361A (pt) antagonistas do receptor muscarìnico de acetilcolina
BR0007864A (pt) Composto, e, uso de um composto
MX9801987A (es) Nuevos derivados de aminoacido, su obtencion y su uso.
BR0108454A (pt) Métodos para identificação e uso de antagonistas de receptor de adenosina a(2b) papa mediar a proliferação celular em mamìferos
WO2000006597A3 (en) Endogenous constitutively activated g protein-coupled orphan receptors
WO2004108887A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
ATE273389T1 (de) Rezeptor des y-y5 neuropeptids
EP1023269A4 (en) BETA3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF USE
TR199900430T2 (xx) �kameli 1,2,3,4-tetrahidro-2-dibenzofuranaminler ve 2-aminosiklohepta$b] benzofuranlar.
ES2191625T3 (es) Composicion oral que contiene perlita.
DE69903716D1 (de) Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten